Investment Thesis
Alnylam 1-year share price performance. Source: TradingView
Alnylam (ALNY) is arguably the best known and most advanced developer of RNAi therapeutics - using small interfering RNA ("siRNA") to identify messenger RNA ("mRNA") and disrupt the process by which it encodes disease causing proteins. This is also often referred to as gene-silencing, or "switching off" the production of mutant proteins.
RNAi therapeutics is enjoying a strong "second wind", after the initial promise of the 2006 Nobel Prize-winning science fizzled out as companies such as Alnylam, Dicerna (DRNA) and Sirna -